SDC4 identified as an oncogenic target gene of NF-κB in TNFα-Induced tumor cells

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Signaling

Background:

• Syndecan-4 (SDC4), a proteoglycan, is implicated in cell signaling but its role in cancer is unclear.
• SDC4 overexpression is observed in numerous tumor types, correlating with poor patient prognosis.
• Understanding SDC4 regulation is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate the role and regulatory mechanisms of SDC4 in tumor progression.
• To identify key transcription factors involved in SDC4 regulation.
• To explore the therapeutic potential of targeting the SDC4 pathway in cancer.

Main Methods:

• Bioinformatic analysis of SDC4 expression and patient prognosis data.
• In vitro studies involving SDC4 knockdown, gene expression analysis (qRT-PCR, Western blot), and protein localization (Immunofluorescence).
• Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to assess transcription factor binding and histone modifications.

Main Results:

• SDC4 is overexpressed in 16 tumor types and linked to poor prognosis in four.
• Knockdown of SDC4 reduced tumor cell migration.
• NF-κB was identified as a key transcription factor regulating SDC4, with TNFα stimulation enhancing NF-κB binding to the SDC4 promoter and increasing SDC4 expression.
• Inhibition of NF-κB blocked TNFα-induced SDC4 upregulation.
• SDC4 expression positively correlated with NF-κB subunit RelA across 22 tumor types.

Conclusions:

• SDC4 acts as an oncogenic gene regulated by NF-κB signaling.
• The NF-κB/SDC4 axis represents a promising therapeutic target for anti-cancer strategies.
• This research provides novel insights into SDC4's function and regulation in tumorigenesis.